Trinity Financial Advisors LLC Lowers Position in Johnson & Johnson (NYSE:JNJ)

Trinity Financial Advisors LLC lessened its position in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 68.3% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 856 shares of the company's stock after selling 1,848 shares during the quarter. Trinity Financial Advisors LLC's holdings in Johnson & Johnson were worth $142,000 at the end of the most recent quarter.

Several other large investors have also made changes to their positions in JNJ. Bard Financial Services Inc. increased its holdings in shares of Johnson & Johnson by 0.3% in the first quarter. Bard Financial Services Inc. now owns 100,317 shares of the company's stock worth $16,637,000 after acquiring an additional 289 shares in the last quarter. USA Financial Formulas increased its holdings in shares of Johnson & Johnson by 24.7% in the first quarter. USA Financial Formulas now owns 1,434 shares of the company's stock worth $238,000 after acquiring an additional 284 shares in the last quarter. Curbstone Financial Management Corp increased its holdings in shares of Johnson & Johnson by 0.7% in the first quarter. Curbstone Financial Management Corp now owns 26,921 shares of the company's stock worth $4,465,000 after acquiring an additional 189 shares in the last quarter. CX Institutional grew its holdings in shares of Johnson & Johnson by 6.6% during the first quarter. CX Institutional now owns 62,134 shares of the company's stock worth $10,304,000 after buying an additional 3,821 shares in the last quarter. Finally, Assenagon Asset Management S.A. grew its holdings in shares of Johnson & Johnson by 75.7% during the first quarter. Assenagon Asset Management S.A. now owns 1,601,872 shares of the company's stock worth $265,654,000 after buying an additional 690,168 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company's stock.

Johnson & Johnson Stock Performance

Shares of Johnson & Johnson stock traded up $0.24 during trading hours on Friday, hitting $156.90. 6,587,488 shares of the company's stock traded hands, compared to its average volume of 7,963,253. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $169.99. The stock has a market capitalization of $377.52 billion, a price-to-earnings ratio of 23.59, a PEG ratio of 2.56 and a beta of 0.42. The company has a fifty day simple moving average of $153.84 and a 200-day simple moving average of $153.71. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last posted its quarterly earnings results on Tuesday, April 15th. The company reported $2.77 earnings per share for the quarter, topping the consensus estimate of $2.59 by $0.18. The company had revenue of $21.89 billion during the quarter, compared to the consensus estimate of $21.65 billion. Johnson & Johnson had a return on equity of 34.24% and a net margin of 18.20%. Equities research analysts anticipate that Johnson & Johnson will post 10.58 EPS for the current fiscal year.

Johnson & Johnson Increases Dividend

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were paid a $1.30 dividend. The ex-dividend date of this dividend was Tuesday, May 27th. This represents a $5.20 annualized dividend and a yield of 3.31%. This is an increase from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio (DPR) is currently 57.84%.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on JNJ shares. Wall Street Zen downgraded Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Bank of America decreased their price objective on Johnson & Johnson from $171.00 to $159.00 and set a "neutral" rating for the company in a report on Thursday, April 10th. Leerink Partners downgraded Johnson & Johnson from an "outperform" rating to a "market perform" rating and decreased their price objective for the stock from $169.00 to $153.00 in a report on Tuesday, May 13th. Barclays decreased their price objective on Johnson & Johnson from $166.00 to $165.00 and set an "equal weight" rating for the company in a report on Thursday, April 17th. Finally, Benchmark upgraded Johnson & Johnson to a "strong-buy" rating in a report on Thursday, April 24th. Eleven investment analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus price target of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.